The role of glycogen synthase kinase-3β in glioma cell apoptosis induced by remifentanil

• Autorzy: Xu J , Xu P. , Li Z. , Xiao L. , Yang Z.
• Języki publikacji: EN

Abstrakty

EN

The aim of malignant glioma treatment is to inhibit tumor cell proliferation and induce tumor cell apoptosis. Remifentanil is a clinical anesthetic drug that can activate the N-methyl-D-aspartate (NMDA) receptor. NMDA receptor signaling activates glycogen synthase kinase-3β (GSK-3β). Discovered some 32 years ago, GSK-3β was only recently considered as a therapeutic target in cancer treatment. The purpose of this study was to assess whether remifentanil can induce the apoptosis of C6 cells through GSK-3β activation. 3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was used to detect cell viability. Hoechst 33342 staining and flow cytometry were used to detect cell apoptosis. The effect of GSK-3β activation was detected using a GSK-3β activation assay kit and 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a potent and selective small molecule inhibitor of GSK-3β. The MTT assay indicated that remifentanil induced C6 cell death in a concentration- and time-dependent manner. Hoechst 33342 staining and flow cytometry showed that remifentanil significantly induced C6 cell apoptosis. The measurement of GSK-3β activation showed that remifentanil increased the cellular level of GSK-3β. All of these toxic effects can be attenuated by treatment with TDZD-8. These results suggest that remifentanil is able to induce C6 cell apoptosis through GSK-3β activation, which provides a basis for its potential use in the treatment of malignant gliomas.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2013
• Tom: 18
• Numer: 4
• Opis fizyczny: p.494-506,fig.,ref.

Twórcy

autor

Xu J

• College of Medicine, Nankai University, Tianjin, 300071, China

autor

Xu P.

• College of Medicine, Nankai University, Tianjin, 300071, China

autor

Li Z.

• College of Medicine, Nankai University, Tianjin, 300071, China

autor

Xiao L.

• College of Medicine, Nankai University, Tianjin, 300071, China

autor

Yang Z.

• College of Medicine, Nankai University, Tianjin, 300071, China

Bibliografia

• 1. Scott, C.B., Scarantino, C., Urtasun, R., Movsas, B., Jones, C.U., Simpson, J.R., Fischbach, A.J. and Curran, W.J., Jr. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int. J. Radiat. Oncol. Biol. Phys. 40 (1998) 51-55.
• 2. Bogler, O. and Weller, M. Apoptosis in gliomas, and its role in their current and future treatment. Front. Biosci. 7 (2002) 339-353.
• 3. Hahnenkamp, K., Nollet, J., Van Aken, H.K., Buerkle, H., Halene, T., Schauerte, S., Hahnenkamp, A., Hollmann, M.W., Strumper, D., Durieux, M.E. and Hoenemann, C.W. Remifentanil directly activates human N-methyl-D-aspartate receptors expressed in Xenopus laevis oocytes. Anesthesiology 100 (2004) 1531-1537.
• 4. Guntz, E., Dumont, H., Roussel, C., Gall, D., Dufrasne, F., Cuvelier, L., Blum, D., Schiffmann, S.N. and Sosnowski, M. Effects of remifentanil on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord. Anesthesiology 102 (2005) 1235-1241.
• 5. Zhao, M. and Joo, D.T. Enhancement of spinal N-methyl-D-aspartate receptor function by remifentanil action at delta-opioid receptors as a mechanism for acute opioid-induced hyperalgesia or tolerance. Anesthesiology 109 (2008) 308-317.
• 6. Joly, V., Richebe, P., Guignard, B., Fletcher, D., Maurette, P., Sessler, D.I. and Chauvin, M. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 103 (2005) 147-155.
• 7. Luo, H.R., Hattori, H., Hossain, M.A., Hester, L., Huang, Y., Lee-Kwon, W., Donowitz, M., Nagata, E. and Snyder, S.H. Akt as a mediator of cell death. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11712-11717.
• 8. De, Sarno. P., Bijur, G.N., Zmijewska, A.A., Li, X. and Jope, R.S. In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol. Aging 27 (2006) 413-422.
• 9. Svenningsson, P., Tzavara, E.T., Carruthers, R., Rachleff, I., Wattler, S., Nehls, M., McKinzie, D.L., Fienberg, A.A., Nomikos, G.G. and Greengard, P. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415.
• 10. Doble, B.W. and Woodgett, J.R. GSK-3: tricks of the trade for a multitasking kinase. J. Cell. Sci. 116 (2003) 1175-1186.
• 11. Cohen, P. and Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3 (2004) 479-487.
• 12. Watcharasit, P., Bijur, G.N., Song, L., Zhu, J., Chen, X. and Jope, R.S. Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J. Biol. Chem. 278 (2003) 48872-48879.
• 13. Hetman, M., Cavanaugh, J.E., Kimelman, D. and Xia, Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 20 (2000) 2567-2574.
• 14. Bijur, G.N., De, Sarno. P. and Jope, R.S. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J. Biol. Chem. 275 (2000) 7583-7590.
• 15. Hemmings, B.A., Yellowlees, D., Kernohan, J.C. and Cohen, P. Purification of glycogen synthase kinase 3 from rabbit skeletal muscle. Copurification with the activating factor (FA) of the (Mg-ATP) dependent protein phosphatase. Eur. J. Biochem. 119 (1981) 443-451.
• 16. Huang, S.M., Cheung, C.W., Chang, C.S., Tang, C.H., Liu, J.F., Lin, Y.H., Chen, J.H., Ko, S.H., Wong, K.L. and Lu, D.Y. Phloroglucinol derivative MCPP induces cell apoptosis in human colon cancer. J. Cell. Biochem. 112 (2011) 643-652.
• 17. Wang, Z., Smith, K.S., Murphy, M., Piloto, O., Somervaille, T.C. and Cleary, M.L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455 (2008) 1205-1209.
• 18. Foltz, D.R., Santiago, M.C., Berechid, B.E. and Nye, J.S. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr. Biol. 12 (2002) 1006-1011.
• 19. Singler, B., Troster, A., Manering, N., Schuttler, J. and Koppert, W. Modulation of remifentanil-induced postinfusion hyperalgesia by propofol. Anesth. Analg. 104 (2007) 1397-1403.
• 20. Benda, P., Lightbody, J., Sato, G., Levine, L. and Sweet, W. Differentiated rat glial cell strain in tissue culture. Science 161 (1968) 370-371.
• 21. Auer, R.N., Del Maestro, R.F. and Anderson, R. A simple and reproducible experimental in vivo glioma model. Can. J. Neurol. Sci. 8 (1981) 325-331.
• 22. Denizot, F. and Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89 (1986) 271-277.
• 23. Martinez, A., Alonso, M., Castro, A., Perez, C. and Moreno, F.J. First nonATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45 (2002) 1292-1299.
• 24. Hui, W., Litherland, G.J., Jefferson, M., Barter, M.J., Elias M.S., Cawston, T.E., Rowan, A.D. and Young, D.A. Lithium protects cartilage from cytokinemediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology (Oxford) 49 (2010) 2043-2053.
• 25. Shiu, L.Y., Liang, C.H., Huang, Y.S., Sheu, H.M. and Kuo, K.W. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu. Cell. Biol. Toxicol. 24 (2008) 1-10.
• 26. Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell 100 (2000) 57-70.
• 27. Mao, J., Price, D.D., Lu, J. and Mayer, D.J. Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats. Neurosci. Lett. 250 (1998) 193-196.
• 28. Chen, L. and Huang, L.Y. Sustained potentiation of NMDA receptormediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron 7 (1991) 319-326.
• 29. Ma, T., Zhao, Y., Kwak, Y.D., Yang, Z., Thompson, R., Luo, Z., Xu, H. and Liao, F.F. Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J. Neurosci. 29 (2009) 11226-11236.
• 30. Barth, A.I., Nathke, I.S. and Nelson, W.J. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr. Opin. Cell. Biol. 9 (1997) 683-690.
• 31. Grimes, C.A. and Jope, R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65 (2001) 391-426.
• 32. Pap, M. and Cooper, G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J. Biol. Chem. 273 (1998) 19929-19932.
• 33. Crowder, R.J. and Freeman, R.S. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J. Biol. Chem. 275 (2000) 34266-34271.
• 34. Korur, S., Huber, R.M., Sivasankaran, B., Petrich, M., Morin, P, Jr., Hemmings, B.A., Merlo, A. and Lino, M.M. GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One 4 (2009) 7443.
• 35. Tan, J., Zhuang, L., Leong, H.S., Iyer, N.G., Liu, E.T. and Yu, Q. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res. 65 (2005) 9012-9020.
• 36. Linseman, D.A., Butts, B.D., Precht, T.A., Phelps, R.A., Le, S.S., Laessig, T.A., Bouchard, R.J., Florez-McClure, M.L. and Heidenreich, K.A. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J. Neurosci. 24 (2004) 9993-10002.
• 37. Perez, M., Rojo, A.I., Wandosell, F., Diaz-Nido, J. and Avila, J. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem. J. 372 (2003) 129-136.
• 38. Bajic, V.P., Su, B., Lee, H.G., Kudo, W., Siedlak, S.L., Zivkovic, L., Spremo-Potparevic, B., Djelic, N., Milicevic, Z., Singh, A.K., Fahmy, L.M., Wang, X., Smith, M.A. and Zhu, X. Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease. Cell. Mol. Biol. Lett. 16 (2011) 359-372.
• 39. Cali, T., Ottolini, D. and Brini, M. Mitochondrial Ca(2+) and neurodegeneration. Cell Calcium 52 (2012) 73-85.
• 40. Vianna, P.T., Castiglia, Y.M., Braz, J.R., Viero, R.M., Beier, S., Vianna Filho, P.T., Vitoria, A., Reinoldes Bizarria Guilherme, G., de Assis Golim, M. and Deffune, E. Remifentanil, isoflurane, and preconditioning attenuate renal ischemia/reperfusion injury in rats. Transplant Proc. 41 (2009) 4080- 4082.
• 41. Yang, L.Q., Tao, K.M., Liu, Y.T., Cheung, C.W., Irwin, M.G., Wong, G.T., Lv, H., Song, J.G., Wu, F.X. and Yu, W.F. Remifentanil preconditioning reduces hepatic ischemia-reperfusion injury in rats via inducible nitric oxide synthase expression. Anesthesiology 114 (2011) 1036-1047.
• 42. Kim, H.S., Cho, J.E., Hong, S.W., Kim, S.O., Shim, J.K. and Kwak, Y.L. Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. Physiol. Res. 59 (2010) 347-356.
• 43. Park, S.W., Yi, J.W., Kim, Y.M., Kang, J.M., Kim, D.O., Shin, M.S., Kim, C.J., Lee, D.I., Kim, D.H. and Lee, B.J. Remifentanil alleviates transient cerebral ischemia-induced memory impairment through suppression of apoptotic neuronal cell death in gerbils. Korean J. Anesthesiol. 61 (2011) 63-68.

Uwagi

rekord w opracowaniu